Professor Dean Fennell FMedSci

Dean Fennell is Director of the Mesothelioma Research Programme at the University of Leicester. He is a world leader in precision medicine-based strategies for this rare cancer and co-discovered the first actionable epigenetic drug target, leading two decades later to the first ever positive phase III trial of a targeted agent. His translational research has pioneered the study of mesothelioma evolution to identify new druggable vulnerabilities for translation into the clinic. Professor Fennell is the world’s leading researcher in the field of mesothelioma, linking scientific discovery to practice-changing clinical trials and the improvement of patient outcomes.